Elizabeth Budde

832 total citations
26 papers, 275 citations indexed

About

Elizabeth Budde is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Elizabeth Budde has authored 26 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 7 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Elizabeth Budde's work include CAR-T cell therapy research (19 papers), Lymphoma Diagnosis and Treatment (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Elizabeth Budde is often cited by papers focused on CAR-T cell therapy research (19 papers), Lymphoma Diagnosis and Treatment (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Elizabeth Budde collaborates with scholars based in United States, Australia and Canada. Elizabeth Budde's co-authors include Ibrahim Aldoss, Stephen J. Forman, Samer K. Khaled, Anthony S. Stein, Enkhtsetseg Purev, Brett M. Stevens, Steven T. Rosen, Vinod Pullarkat, Craig T. Jordan and Jonathan A. Gutman and has published in prestigious journals such as Blood, Cancer Research and Journal of Cellular Physiology.

In The Last Decade

Elizabeth Budde

24 papers receiving 273 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elizabeth Budde United States	9	161	105	88	63	48	26	275
Rawan Faramand United States	10	210 1.3×	154 1.5×	115 1.3×	39 0.6×	57 1.2×	37	375
S. Schuster United States	6	199 1.2×	41 0.4×	79 0.9×	124 2.0×	123 2.6×	11	330
Maria Laura Milani Italy	6	176 1.1×	75 0.7×	118 1.3×	90 1.4×	88 1.8×	11	326
Kaiyang Ding China	9	113 0.7×	100 1.0×	107 1.2×	36 0.6×	46 1.0×	51	241
Yoshiaki Kuroda Japan	12	161 1.0×	204 1.9×	222 2.5×	46 0.7×	71 1.5×	36	403
Rodica Morariu-Zamfir United States	8	232 1.4×	58 0.6×	104 1.2×	110 1.7×	96 2.0×	15	385
Patricia Kropf United States	9	59 0.4×	193 1.8×	138 1.6×	42 0.7×	49 1.0×	26	341
Juan Esteban García-Robledo United States	9	102 0.6×	68 0.6×	64 0.7×	18 0.3×	77 1.6×	33	266
Bryan Do United States	6	187 1.2×	49 0.5×	32 0.4×	79 1.3×	53 1.1×	7	288
Raphael Teipel Germany	8	72 0.4×	59 0.6×	137 1.6×	17 0.3×	30 0.6×	21	196

Countries citing papers authored by Elizabeth Budde

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Budde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Budde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Budde more than expected).

Fields of papers citing papers by Elizabeth Budde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Budde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Budde. The network helps show where Elizabeth Budde may publish in the future.

Co-authorship network of co-authors of Elizabeth Budde

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Budde. A scholar is included among the top collaborators of Elizabeth Budde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Budde. Elizabeth Budde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xiao, Annie, Lu Chen, Matthew Mei, et al.. (2025). Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma. Leukemia & lymphoma. 66(12). 2260–2268.

Baird, John H., Geoffrey Shouse, Liana Nikolaenko, et al.. (2024). High Incidence of Cytomegalovirus (CMV) Reactivation in Patients Receiving CAR T-Cell Therapy.. Transplantation and Cellular Therapy. 30(2). S227–S227.

Tran, Ben, Michael E. Hurwitz, Adrian G. Sacher, et al.. (2022). 558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study. Regular and Young Investigator Award Abstracts. A584–A584. 27 indexed citations

Budde, Elizabeth, Ajay K. Gopal, Won Seog Kim, et al.. (2021). A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. Blood. 138(Supplement 1). 132–132. 22 indexed citations

Teh, Jennifer Berano, Teresa Vera, Kyuwan Lee, et al.. (2021). Sarcopenia Is a Clinically Relevant and Independent Predictor of Health Outcomes after Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Blood. 138(Supplement 1). 2502–2502. 5 indexed citations

Siddiqi, Tanya, Xiuli Wang, M. Suzette Blanchard, et al.. (2021). Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL). Blood. 138(Supplement 1). 2836–2836. 1 indexed citations

Salhotra, Amandeep, Ahmed Aribi, Dat Ngo, et al.. (2021). Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA‐Ven) or liposomal daunorubicin‐cytarabine (CPX‐351). American Journal of Hematology. 96(6). E196–E200. 8 indexed citations

Diefenbach, Catherine, Elizabeth Budde, Julio C. Chávez, et al.. (2021). PROMISING CLINICAL DATA FROM DOSE ESCALATION IN A PHASE IB/II ONGOING STUDY OF MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN FOR RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMA. Hematological Oncology. 39(S2). 4 indexed citations

Budde, Elizabeth, Nilanjan Ghosh, Julio C. Chávez, et al.. (2021). ABCL-351: Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). Clinical Lymphoma Myeloma & Leukemia. 21. S393–S394. 1 indexed citations

10.

Salhotra, Amandeep, Dongyun Yang, Sally Mokhtari, et al.. (2020). Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 26(6). 1084–1090. 15 indexed citations

11.

Aldoss, Ibrahim, Samer K. Khaled, Elizabeth Budde, & Anthony S. Stein. (2019). Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment. Current Oncology Reports. 21(1). 4–4. 29 indexed citations

12.

Stevens, Brett M., Wei Zhang, Daniel A. Pollyea, et al.. (2019). CD123 CAR T cells for the treatment of myelodysplastic syndrome. Experimental Hematology. 74. 52–63.e3. 35 indexed citations

13.

Nguyen, Le Xuan Truong, Estelle Troadec, Bijender Kumar, et al.. (2019). The Bcl‐2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. Journal of Cellular Physiology. 234(8). 14040–14049. 54 indexed citations

14.

Salhotra, Amandeep, Matthew Mei, Tracey Stiller, et al.. (2018). Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. Biology of Blood and Marrow Transplantation. 25(2). 287–292. 5 indexed citations

15.

Mohanty, Atish, Thang Van Nguyen, Robert W. Chen, et al.. (2018). Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood. 133(4). 306–318. 27 indexed citations

16.

Zhang, Wei, Brett M. Stevens, Elizabeth Budde, et al.. (2017). Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic Syndrome. Blood. 130. 1917–1917. 8 indexed citations

17.

Popplewell, Leslie, Xiuli Wang, Araceli Naranjo, et al.. (2015). Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. Blood. 126(23). 930–930. 3 indexed citations

18.

Urak, Ryan, Wen-Chung Chang, Elizabeth Budde, et al.. (2015). Ex Vivo AKT Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy. Blood. 126(23). 3086–3086. 2 indexed citations

19.

Wang, Xiuli, ChingLam W. Wong, Ryan Urak, et al.. (2014). CS-1 Re-Directed Central Memory T Cell Therapy for Multiple Myeloma. Blood. 124(21). 1114–1114. 2 indexed citations

20.

Park, Steven I., Kristy L. Richards, Oludamilola Olajide, et al.. (2014). A Phase 2 Trial of Induction Chemotherapy with ABVD Followed By Brentuximab Vedotin Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma. Blood. 124(21). 4431–4431. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact